CardioSignal has been selected as the winner of Desafío DKV 2025, the open innovation challenge organised by DKV Innolab and announced during the Health4Good event in Barcelona.

CardioSignal takes heart health monitoring to a higher standard with its latest update, now fully compliant as a Class IIb medical device under the European Medical Device Regulation (MDR).

CardioSignal is now MDR Class IIb certified and is preparing to launch CardioSignal Inside, an SDK that enables partners to integrate CE-marked Afib detection and heart rate measurement into their mobile apps.

CardioSignal and LocalTapiola launch a nationwide atrial fibrillation case-finding initiative. LocalTapiola offers 5,000 customers aged 50–75 free access to CardioSignal’s one-minute smartphone-based Afib detection app. The partnership aims to improve early detection, reduce stroke risk, and support preventive care with an easy-to-use digital solution.

CardioSignal is pleased to announce the appointment of Dr. Blaž Mrevlje as its new Medical Director. In this role, Dr. Mrevlje will lead medical development at CardioSignal, contributing his expertise in clinical research, regulatory documentation, and medical communication to further advance the company's innovative solutions for heart disease detection.

CardioSignal announces a collaboration with Heart Center Mølholm, one of Denmark’s most esteemed private hospitals and pioneers in cutting-edge cardiac ablation. This partnership marks a significant step forward in improving post-procedure care for patients undergoing ablation treatment at Mølholm.